February 28, 2020
Taiho Pharmaceutical said on February 27 that it has acquired exclusive rights to develop and market the anti-PD-1 antibody AB122, which is currently being developed by the US-based Arcus Biosciences, in Japan and Asia excluding China and Thailand. Taiho concluded...read more